Depleting hepatitis B virus relaxed circular DNA is necessary for resolution of infection by CRISPR-Cas9

• Main Authors: Dmitry Kostyushev (Author), Anastasiya Kostyusheva (Author), Sergey Brezgin (Author), Natalia Ponomareva (Author), Natalia F. Zakirova (Author), Aleksandra Egorshina (Author), Dmitry V. Yanvarev (Author), Ekaterina Bayurova (Author), Anna Sudina (Author), Irina Goptar (Author), Anastasiya Nikiforova (Author), Elena Dunaeva (Author), Tatiana Lisitsa (Author), Ivan Abramov (Author), Anastasiia Frolova (Author), Alexander Lukashev (Author), Ilya Gordeychuk (Author), Andrey A. Zamyatnin, Jr (Author), Alexander Ivanov (Author), Vladimir Chulanov (Author)
• Format: Book
• Published: Elsevier, 2023-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

CRISPR-Cas9 systems can directly target the hepatitis B virus (HBV) major genomic form, covalently closed circular DNA (cccDNA), for decay and demonstrate remarkable anti-HBV activity. Here, we demonstrate that CRISPR-Cas9-mediated inactivation of HBV cccDNA, frequently regarded as the "holy gr...